title: Tanshinone IIA prevents cardiac remodeling through attenuating NAD (P)H oxidase-derived reactive oxygen species production in hypertensive rats.
abstract: Tanshinone IIA is one of major constituents of Salvia miltiorrhiza Bunge known as Danshen. Our and others' studies have shown that Tan IIA could protect cardimyocyte against apoptosis; however the effect of Tan IIA on cardiac remodeling disease is still unknown. In this study, we investigated the effects of Tan IIA on cardiac hypertrophy and fibrosis in two-kidney, two-clip (2K2C) hypertensive rats and by which, if any, mechanisms. Administration of 2K2C hypertensive rats with Tan IIA attenuated cardiac dysfunction and fibrosis. However Tan IIA treatment had no effects on BP control. Further studies revealed that Tan IIA inhibited the increased NAD(P)H oxidase activity and expression as well as O2*- production in 2K2C hypertensive rats. Our results indicated that Tan IIA significantly improved cardiac function and attenuated fibrosis in 2K2C hypertensive rats. The protective action of Tan IIA is likely mediated by its antioxidant effect, independent of BP control, partially via inhibiting NADPH oxidase.
authors.affiliation: Laboratory of Pharmacology and Toxicology, School of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou, China.
authors.forename: Ping
authors.initials: P
authors.lastname: Wang
authors.forename: Xiaoqian
authors.initials: X
authors.lastname: Wu
authors.forename: Yingxia
authors.initials: Y
authors.lastname: Bao
authors.forename: Jian
authors.initials: J
authors.lastname: Fang
authors.forename: Sigui
authors.initials: S
authors.lastname: Zhou
authors.forename: Jie
authors.initials: J
authors.lastname: Gao
authors.forename: Rongbiao
authors.initials: R
authors.lastname: Pi
authors.forename: Yong-Gao
authors.initials: YG
authors.lastname: Mou
authors.forename: Peiqing
authors.initials: P
authors.lastname: Liu
mesh_terms: D045784:Abietanes / Q000494:pharmacology*; D000818:Animals; D015153:Blotting, Western; D006332:Cardiomegaly / Q000378:metabolism / Q000473:pathology / Q000517:prevention & control*; D002316:Cardiotonic Agents; D003326:Coronary Circulation / Q000187:drug effects; D004791:Enzyme Inhibitors; D005355:Fibrosis; D006331:Heart Diseases / Q000000981:diagnostic imaging / Q000517:prevention & control; D006439:Hemodynamics / Q000187:drug effects; D006978:Hypertension, Renovascular / Q000378:metabolism / Q000473:pathology*; D008297:Male; D009206:Myocardium / Q000473:pathology; D019255:NADPH Oxidases / Q000037:antagonists & inhibitors*; D051381:Rats; D017207:Rats, Sprague-Dawley; D017382:Reactive Oxygen Species / Q000378:metabolism*; D020133:Reverse Transcriptase Polymerase Chain Reaction; D013318:Stroke Volume / Q000187:drug effects; D014463:Ultrasonography; D018487:Ventricular Dysfunction, Left / Q000473:pathology / Q000517:prevention & control
chemical_list: D045784:Abietanes; D002316:Cardiotonic Agents; D004791:Enzyme Inhibitors; D017382:Reactive Oxygen Species; C021751:tanshinone; D019255:NADPH Oxidases